Intelligent Bio Solutions Inc (NASDAQ: INBS) May Be Attracting Institutional Investments

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

Intelligent Bio Solutions Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Medical Devices industry. The current market capitalization of Intelligent Bio Solutions Inc is $8.94M. A total of 5.6 million shares were traded on the day, compared to an average of 1.62 shares.

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, INBS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 4 BUYs and 0 SELLs from insiders. Insiders purchased 11,639 shares during that period but sold 0.

In the most recent transaction, Simeonidis Harry bought 50 shares of INBS for 1.85 per share on Sep 01. After the transaction, the CEO now owns 4,180 company shares. In a previous transaction on Aug 31, Simeonidis Harry bought 100 shares at 1.92 per share. INBS shares that CEO owns now total 4,130.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for INBS in the last 3 months, the mean price target is $72.00 with high estimates of $72.00 and low estimates of $72.00. In terms of 52-week highs and lows, INBS has a high of $135.48 and a low of $2.28.

As of this writing, INBS has an earnings estimate of -$2.52 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$2.52 per share and a lower estimate of -$2.52. The company reported an EPS of -$22.92 in the last quarter, which was -28.20% lower than expectations of -$17.88.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. INBS’s latest balance sheet shows that the firm has $8.24M in Cash & Short Term Investments as of fiscal 2022. There were $0.00 in debt and $4.66M in liabilities at the time. Its Book Value Per Share was $0.19, while its Total Shareholder’s Equity was $6.55M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for INBS is Buy with a score of 5.00.

Most Popular

Related Posts